NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

Core Points - NRx Pharmaceuticals will release its Q1 2025 financial results on May 15, 2025, after market close, followed by a conference call at 4:30 PM ET to discuss the results and provide a corporate update [1][2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [3] - The company is developing NRX-101, which has received FDA-designated Breakthrough Therapy status for treating suicidal treatment-resistant bipolar depression and chronic pain, with plans to file for Accelerated Approval [3] - NRx has initiated a New Drug Application for NRX-100 (IV ketamine) for suicidal depression, based on clinical trial results and data from French health authorities [4] Subsidiary Information - HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is establishing a network of interventional psychiatry clinics to provide ketamine and other therapies for suicidal depression and related disorders [5]